Rachid Baz, MD
Hematology & Oncology · Tampa, FLNPI 1831393875
Payments from drug & device makers
Across 397 payments — averaging $7588.92 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Bristol Myers Squibb$1.2M
- AbbVie$935K
- Regeneron$375K
- Janssen Research & Development, LLC$291K
- E.r. Squibb & Sons, L.L.C.$54K
- Takeda Pharmaceuticals U.S.A., Inc.$30K
- plus $104K from 16 others
Across 31 payments — averaging $271.75 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Regeneron$8K
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Bristol Myers Squibb | 22 | $1,224,071 |
| AbbVie | 190 | $934,849 |
| Regeneron | 69 | $374,625 |
| Janssen Research & Development, LLC | 38 | $290,540 |
| E.r. Squibb & Sons, L.L.C. | 2 | $54,002 |
| Takeda Pharmaceuticals U.S.A., Inc. | 3 | $30,370 |
| Karyopharm Therapeutics Inc. | 8 | $29,403 |
| Hikma Pharmaceuticals USA | 9 | $29,285 |
| GSK | 9 | $17,656 |
| Sanofi | 15 | $13,395 |
| Sanofi US Services Inc. | 2 | $4,170 |
| Merck | 3 | $2,525 |
| Janssen Scientific Affairs, LLC | 2 | $2,053 |
| Johnson & Johnson | 10 | $1,903 |
| Pfizer | 1 | $1,750 |
| Genentech, Inc. | 1 | $1,320 |
| Amgen | 6 | $432 |
| Stemline Therapeutics Inc. | 1 | $127 |
| Lilly USA, LLC | 3 | $125 |
| Gilead | 1 | $114 |
| Beigene USA, Inc. | 1 | $69 |
| Sanofi-aventis U.S. LLC | 1 | $19 |
How this compares
$3,012,801 in reported general payments places this provider in the 90th percentile of 694 hematology & oncology providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other hematology & oncology in Tampa
- Julio ChavezTampa$16.4M
- Frederick LockeTampa$12.8M
- Richard KimTampa$8.5M
- David SallmanTampa$7.2M
- Andrew BrohlTampa$6.5M
- Bijal ShahTampa$5.7M
- Jonathan ChatzkelTampa$4.2M
- Sonam PuriTampa$3.9M
- Hatem SolimanTampa$3.7M
- Iman ImaniradTampa$3.2M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.